[{"id":"53e4c97f-4e2e-462d-918b-491a917e56c0","acronym":"PYNNACLE","url":"https://clinicaltrials.gov/study/NCT04585750","created_at":"2022-08-16T14:56:01.466Z","updated_at":"2025-02-25T16:10:42.353Z","phase":"Phase 1/2","brief_title":"The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)","source_id_and_acronym":"NCT04585750 - PYNNACLE","lead_sponsor":"PMV Pharmaceuticals, Inc","biomarkers":" TP53","pipe":" | ","alterations":" TP53 mutation • TP53 Y220C","tags":["TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • TP53 Y220C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • rezatapopt (PC14586)"],"overall_status":"Recruiting","enrollment":" Enrollment 230","initiation":"Initiation: 10/29/2020","start_date":" 10/29/2020","primary_txt":" Primary completion: 03/17/2026","primary_completion_date":" 03/17/2026","study_txt":" Completion: 07/14/2026","study_completion_date":" 07/14/2026","last_update_posted":"2024-12-04"}]